How peptide prescribing works online, end to end

A peptide program looks simple from the outside: a patient asks, a clinician signs, a package arrives. The work is in the order of those steps, and in being able to show, later, who did what.

The path a request takes

1. The patient answers health questions once, then the questions for the medicine they are asking about.
2. Those answers are screened against the rules for that medicine, and the result is put in front of a clinician.
3. A licensed provider at the clinic reviews the case and either signs with directions, declines with a reason, or asks the patient a question.
4. Only after a signature does anything move: the order is created, the patient pays, and the medicine is prepared and shipped.
5. Follow-up runs on the same record: doses, messages, side-effect reports, refills.

Who may fill it

This is the question every prescriber asks first, and in 2026 it has a narrow answer. A peptide may reach a patient when it is an approved finished drug, or when a licensed United States compounding pharmacy prepares it against that patient’s prescription from a permitted substance. Everything else is somebody else’s risk appetite, not a supply chain.

What changes by state

Your provider must be licensed where the patient sits, not where the clinic sits. Some states ask for more before a first prescription, such as an existing relationship or a video visit, and several require specific notices to be shown at intake. A program that treats states as a list of names rather than a list of rules will get one of them wrong.

What a clinic should be able to prove

• Which provider signed, when, and what they saw at the time.
• The answers the patient gave, and the screening result on top of them.
• A written reason whenever a case was approved against the screening, or declined.
• Where the medicine was prepared, and where it went.

None of that is software for its own sake. It is what turns a program into something a clinic can defend a year later, when somebody asks.